Glycoconjugate vaccines against antimicrobial resistant pathogens

Sorieul, Charlotte; Dolce, Marta; Romano, Maria Rosaria; Codée, Jeroen; Adamo, Roberto

doi:10.1080/14760584.2023.2274955

Cited by 12 publications

(6 citation statements)

References 240 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examples of glycoconjugate vaccines licensed worldwide are the ones against Haemophilus influenzae type b, Neisseria meningitidis serogroup A, C and ACWY, pneumococcal vaccines, which have been expanded from 7 to 20 valent, and Salmonella enterica subsp. enterica serovar Typhi [50]. Continuous broadening of pneumococcal vaccine to cover new strains is needed to overcome serotype replacement and counteract antimicrobial resistance [51].…”

Section: Recent Advancements In Mabsmentioning

confidence: 99%

“…By incorporating in E. coli the glycan operon, along with the oligosaccharyltransferase PglB and the protein-encoding plasmid, it is possible to produce in a single fermentation step the glycoprotein, thus simplifying vaccine manufacturing and preserving the protein epitopes in their natural conformation. Bioconjugates for the prevention of different AMR pathogens, including Shigella, S. aureus, P. aeruginosa and K. pneumoniae, are under development and some candidates have reached the clinical phase (Table 1) [50,53,54]. The most advanced one is a 9-valent vaccine targeting invasive infections caused by Extraintestinal Pathogenic E. coli (ExPEC-9V) [20].…”

Section: Recent Advancements In Mabsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance

La Guidara,

Adamo,

Sala

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Antimicrobial resistance (AMR) is one of the most critical threats to global public health in the 21st century, causing a large number of deaths every year in both high-income and low- and middle-income countries. Vaccines and monoclonal antibodies can be exploited to prevent and treat diseases caused by AMR pathogens, thereby reducing antibiotic use and decreasing selective pressure that favors the emergence of resistant strains. Here, differences in the mechanism of action and resistance of vaccines and monoclonal antibodies compared to antibiotics are discussed. The state of the art for vaccine technologies and monoclonal antibodies are reviewed, with a particular focus on approaches validated in clinical studies. By underscoring the scope and limitations of the different emerging technologies, this review points out the complementary of vaccines and monoclonal antibodies in fighting AMR. Gaps in antigen discovery for some pathogens, as well as challenges associated with the clinical development of these therapies against AMR pathogens, are highlighted.

show abstract

Section: Recent Advancements In Mabsmentioning

confidence: 99%

Section: Recent Advancements In Mabsmentioning

confidence: 99%

Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance

La Guidara,

Adamo,

Sala

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Glycoconjugation is a well-established technology for the development of polysaccharide (PS)-based vaccines and, over the last decades, glycoconjugates have demonstrated great impact on global health [ 1 , 2 , 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines

Oldrini,

Di Benedetto,

Carducci

et al. 2023

Vaccines

View full text Add to dashboard Cite

Glycoconjugate vaccines play a major role in the prevention of infectious diseases worldwide, with significant impact on global health, enabling the polysaccharides to induce immunogenicity in infants and immunological memory. Tetanus toxoid (TT), a chemically detoxified bacterial toxin, is among the few carrier proteins used in licensed glycoconjugate vaccines. The recombinant full-length 8MTT was engineered in E. coli with eight individual amino acid mutations to inactivate three toxin functions. Previous studies in mice showed that 8MTT elicits a strong IgG response, confers protection, and can be used as a carrier protein. Here, we compared 8MTT to traditional carrier proteins TT and cross-reactive material 197 (CRM197), using different polysaccharides as models: Group A Streptococcus cell-wall carbohydrate (GAC), Salmonella Typhi Vi, and Neisseria meningitidis serogroups A, C, W, and Y. The persistency of the antibodies induced, the ability of the glycoconjugates to elicit booster response after re-injection at a later time point, the eventual carrier-induced epitopic suppression, and immune interference in multicomponent formulations were also evaluated. Overall, immunogenicity responses obtained with 8MTT glycoconjugates were compared to those obtained with corresponding TT and, in some cases, were higher than those induced by CRM197 glycoconjugates. Our results support the use of 8MTT as a good alternative carrier protein for glycoconjugate vaccines, with advantages in terms of manufacturability compared to TT.

show abstract

“…Glycoconjugate vaccines are historically robust, safe, and efficient in preventing infections. ,− When developing a glycoconjugate vaccine against a bacteria, a range of carbohydrates on the surface of the bacteria can be targeted, such as the capsule and lipopolysaccharides . In Pa , as the B-band polysaccharide is highly variable, while the A-band polysaccharide is conserved in many clinical isolates, the A-band polysaccharide could therefore be of interest to develop as an antigen to target for a vaccine. − …”

mentioning

confidence: 99%

“… 4 , 7 − 9 When developing a glycoconjugate vaccine against a bacteria, a range of carbohydrates on the surface of the bacteria can be targeted, such as the capsule and lipopolysaccharides. 8 In Pa , as the B-band polysaccharide is highly variable, while the A-band polysaccharide is conserved in many clinical isolates, the A-band polysaccharide could therefore be of interest to develop as an antigen to target for a vaccine. 10 − 12 …”

mentioning

confidence: 99%

Optimization of the Synthesis and Conjugation of the Methyl Rhamnan Tip of Pseudomonas aeruginosa A-Band Polysaccharide and Immunogenicity Evaluation for the Continued Development of a Potential Glycoconjugate Vaccine

Jamshidi,

Cairns,

Huan Khieu

et al. 2024

ACS Infect. Dis.

View full text Add to dashboard Cite

Pseudomonas aeruginosa is an antimicrobial-resistant bacterium that has no vaccine approved for human use. Additionally, it has been identified by the World Health Organization as a priority pathogen for novel vaccines and therapeutic development. We previously developed a synthetic mimic of the A-band polysaccharide tip that showed promise in terms of immunogenicity for use as a glycoconjugate vaccine. In this current manuscript, we improve upon the previous work to continue the development of this glycoconjugate vaccine. Herein, we report a higher-yielding synthesis of mimics containing a handle and a spacer that improved conjugation efficiency, resulting in better carbohydrate-to-protein ratios and also good immunogenicity of these conjugates in mice and rabbits. The data suggested that perhaps only a tetrasaccharide was required to induce an immune response capable of recognizing whole cells of P. aeruginosa.

show abstract

Glycoconjugate vaccines against antimicrobial resistant pathogens

Cited by 12 publications

References 240 publications

Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance

Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance

Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines

Optimization of the Synthesis and Conjugation of the Methyl Rhamnan Tip of Pseudomonas aeruginosa A-Band Polysaccharide and Immunogenicity Evaluation for the Continued Development of a Potential Glycoconjugate Vaccine

Contact Info

Product

Resources

About